Studies suggest the gut microbiome can influence immunotherapy side effects. Butyrate emerges as an intriguing candidate against inflammation in the colon.

How one long noncoding RNA could help improve outcomes in bone marrow and solid organ transplantation.

Patients with cancers of unknown origin greatly benefited from next-generation sequencing; widespread inherited cancer risk also suggests broad utility, a study finds.

University of Michigan research into COVID-19 complications, cancer and surprise medical bills competes among the nation’s top discoveries of the past year.

New technologies are making “precision oncology” more of a reality, including a new approach that better accounts for variations within and across individual cancer types.vidual cancer

Urine test found to be extremely accurate at detecting aggressive prostate cancer with few false negatives.

Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.

Targeting this inside-the-cell checkpoint could potentially improve response to cancer immunotherapy.

A new understanding of intracellular pathways activated as T cells start to mount an immune response offers clues against graft-versus-host disease, a serious complication of bone marrow transplantation.

The liver siphons critical immune cells to render immunotherapy ineffective; radiation to the liver may block this process.

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus.

Implementing policies and strategies to eliminate racial disparities could improve outcomes for both diseases.

A combination approach, which included metabolic reprogramming and immunotherapy, led to complete tumor regression in 60% of study mice.

Throughout the pandemic, researchers have continued to push the boundaries of cancer prevention, diagnosis and treatment.

A new study finds that significant side effects were under-recognized in both younger patients and Black patients being treated for breast cancer.